Quince Therapeutics Q3 2026 Earnings Results & Report

Quince Therapeutics EPS Results

• Actual EPS: -$1.12
• Consensus EPS: -$0.84
• Beat/Miss: Missed by -$0.28
• One Year Ago EPS: N/A

Quince Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Quince Therapeutics (NASDAQ:IRLA) is a clinical-stage biotechnology company developing therapies for rare diseases and other conditions with significant unmet medical needs. The company’s technology platform is designed to use patients’ own red blood cells to deliver therapeutic compounds, with the goal of providing sustained treatment while limiting systemic exposure.

Quince’s lead program is the EryDex System, an investigational treatment that loads dexamethasone sodium phosphate into a patient’s red blood cells for controlled release. The program has been evaluated for ataxia-telangiectasia, a rare inherited disorder affecting neurological, immune and other bodily systems. As an investigational therapy, the EryDex System remains subject to clinical testing and regulatory review.

The company’s operations and clinical development activities have involved the United States and Europe. Quince was formed through a combination with EryDel, the developer of the EryDex technology, and has continued advancing the program through clinical development. Information about additional pipeline programs and current leadership may change as the company’s development strategy evolves.